Bonus Biogroup

Bonus Biogroup Dividend

Dividend of Bonus Biogroup (BONS.TA) as of Nov 22, 2026.

Dividend

0.00ILS

Last updated:

How much dividend does Bonus Biogroup 2026 pay?

According to the latest status from November 2026, Bonus Biogroup paid a total of 0.00 ILS per share in dividends within the last 12 months. With the current Bonus Biogroup price of 14.60 ILS, this corresponds to a dividend yield of - %. A dividend is paid times per year.

Historical Bonus Biogroup Dividends

Historical Bonus Biogroup Dividends
PaydateDividend

The Bonus Biogroup Dividend history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Date
Dividend
Jan 1, 2018
0.00 ILS
Jan 1, 2019
0.00 ILS
Jan 1, 2020
0.00 ILS
Jan 1, 2021
0.00 ILS
Jan 1, 2022
0.00 ILS
Jan 1, 2023
0.00 ILS
Jan 1, 2024
0.00 ILS
Jan 1, 2025
0.00 ILS
The Bonus Biogroup Dividend history
YEARDividendYoY
0.00ILS—
0.00ILS—
0.00ILS—
0.00ILS—
0.00ILS—
0.00ILS—
0.00ILS—
0.00ILS—
0.00ILS—
0.00ILS—
0.00ILS—
0.00ILS—
0.00ILS—
0.00ILS—
0.00ILS—
0.00ILS—
0.00ILS—
0.00ILS—
0.00ILS—
0.00ILS—

Is the Bonus Biogroup Dividend Safe?

Bonus Biogroup has been increasing the dividend for 0 years.

Analysts expect a Dividend Cut of -100.00% for the current fiscal year.

Dividend Details

Understanding Bonus Biogroup's Dividend Distributions

Bonus Biogroup’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Bonus Biogroup's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Bonus Biogroup's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Bonus Biogroup’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Bonus Biogroup Stock analysis

What does Bonus Biogroup do? The Bonus Biogroup Ltd is a biotechnology company based in Israel that specializes in the development and marketing of innovative medical products and therapies based on human bone marrow stem cells. The company was founded in 2008 by a group of scientists, doctors, and entrepreneurs who came together to explore and develop new approaches in regenerative medicine. The business model of Bonus Biogroup is based on utilizing the benefits of stem cells for tissue and organ regeneration. Mesenchymal stem cells (MSC), derived from bone marrow, play an important role in this process. These stem cells have the ability to differentiate into various cell types and have anti-inflammatory properties. Bonus Biogroup aims to utilize MSC technology for the development of innovative medical products and therapies to help patients with serious diseases. The company is divided into several business areas, each offering its own products and services. A key area is the development of implants and other medical devices coated with bone marrow stem cells. These products are intended to promote tissue regeneration in the body, particularly in the treatment of bone and cartilage defects and joint diseases. An example is the BioGrip implant, used in patients with osteoporosis to prevent or reduce bone fractures. Another business area of Bonus Biogroup is the production and marketing of cell therapies. In this process, mesenchymal stem cells are obtained from the patient's bone marrow and processed in a special procedure. The stem cells are then directly injected into the affected area to promote tissue regeneration. These cell therapies are used in patients with rheumatism, arthritis, joint pain, or spinal problems. In addition to research and development of new products and therapies, Bonus Biogroup also operates a large stem cell bank. This bank collects and stores human bone marrow from donors for later use in the production of implants and cell therapies. The stem cell bank is a crucial part of the business model, as it ensures a consistent and high-quality supply of mesenchymal stem cells. In summary, Bonus Biogroup is an innovative biotechnology company specializing in the use of human bone marrow stem cells. The business model is based on the development and marketing of implants, cell therapies, and other medical devices to promote tissue regeneration in the body. The company also operates a large stem cell bank to ensure a consistent supply of high-quality mesenchymal stem cells. The company has the potential to become a significant player in regenerative medicine, making a valuable contribution to improving the health and quality of life of patients. Bonus Biogroup is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bonus Biogroup stock

Bonus Biogroup paid dividends every year for the past 0 years.

Bonus Biogroup is assigned to the 'Health' sector.

The dividends of Bonus Biogroup are distributed in ILS.

Dividend calendar 2026

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

All Key Metrics — Bonus Biogroup